

# Olmesartan (medoxomil)

Catalog No: tcsc0577



## Available Sizes

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg



## Specifications

**CAS No:**

144689-63-4

**Formula:**

$C_{29}H_{30}N_6O_6$

**Pathway:**

GPCR/G Protein

**Target:**

Angiotensin Receptor

**Purity / Grade:**

>98%

**Solubility:**

DMSO : 50 mg/mL (89.51 mM; Need ultrasonic)

**Alternative Names:**

CS 866

**Observed Molecular Weight:**

558.59


## Product Description

Olmesartan medoxomil is a potent and selective **angiotensin AT1 receptor** inhibitor with **IC<sub>50</sub>** of 66.2  $\mu$ M.

IC50 & Target: IC50: 66.2  $\mu$ M (angiotensin II receptor)<sup>[1]</sup>

**In Vitro:** Inhibition of Arachidonic acid (AA) metabolism by angiotensin II receptor blockers (ARBs) is detected in a concentration-dependent manner with IC<sub>50</sub> of Olmesartan (66.2  $\mu$ M)<sup>[1]</sup>. Olmesartan medoxomil (OLM) is a potent and selective angiotensin AT1 receptor blocker<sup>[2]</sup>.

**In Vivo:** The efficacy of Olmesartan (20 mg/kg) studied in db/db diabetic mice for a period of 12 weeks starting from week 10 to 12 of age. The db/db mice have 11.7 fold increased albuminuria in comparison to control mice at week 22 to 24 of age. Twelve weeks Olmesartan administration significantly reduces albuminuria in db/db mice by 77% as compared with placebo treated db/db mice. The albumin/creatinine ratio (ACR) is increased in db/db mice in comparison to control mice by 7.1 fold and Olmesartan treatment significantly decreases ACR by 59% in db/db mice<sup>[3]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!